Literature DB >> 15215529

The human serpin proteinase inhibitor-9 self-associates at physiological temperatures.

Lauren N Benning1, James C Whisstock, Jiuru Sun, Phillip I Bird, Stephen P Bottomley.   

Abstract

The metastable serpin architecture is perturbed by extremes of temperature, pH, or changes in primary sequence resulting in the formation of inactive, polymeric conformations. Polymerization of a number of human serpins in vivo leads to diseases such as emphysema, thrombosis, and dementia, and in these cases mutations are present within the gene encoding the aggregating protein. Here we show that aggregation of the human serpin, proteinase inhibitor-9 (PI-9), occurs under physiological conditions, and forms aggregates that are morphologically distinct from previously characterized serpin polymers. Incubation of monomeric PI-9 at 37 degrees C leads to the rapid formation of aggregated PI-9. Using a variety of spectroscopic methods we analyzed the nature of the structures formed after incubation at 37 degrees C. Electron microscopy showed that PI-9 forms ordered circular and elongated-type aggregates, which also bind the fluorescent dye Thioflavin T. Our data show that in vitro wild-type PI-9 forms aggregates at physiological temperatures. The biological implications of PI-9 aggregates at physiological temperatures are discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15215529      PMCID: PMC2279926          DOI: 10.1110/ps.04715304

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  55 in total

1.  The mechanism of Z alpha 1-antitrypsin accumulation in the liver.

Authors:  D A Lomas; D L Evans; J T Finch; R W Carrell
Journal:  Nature       Date:  1992-06-18       Impact factor: 49.962

2.  The serpins: evolution and adaptation in a family of protease inhibitors.

Authors:  R W Carrell; P A Pemberton; D R Boswell
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1987

Review 3.  What do dysfunctional serpins tell us about molecular mobility and disease?

Authors:  P E Stein; R W Carrell
Journal:  Nat Struct Biol       Date:  1995-02

Review 4.  The serpin superfamily of proteinase inhibitors: structure, function, and regulation.

Authors:  J Potempa; E Korzus; J Travis
Journal:  J Biol Chem       Date:  1994-06-10       Impact factor: 5.157

5.  The ovalbumin family of serpin proteins.

Authors:  E Remold-O'Donnell
Journal:  FEBS Lett       Date:  1993-01-04       Impact factor: 4.124

6.  Production, purification, and characterization of recombinant maspin proteins.

Authors:  S Sheng; P A Pemberton; R Sager
Journal:  J Biol Chem       Date:  1994-12-09       Impact factor: 5.157

7.  Cross-class inhibition of the cysteine proteinases cathepsins K, L, and S by the serpin squamous cell carcinoma antigen 1: a kinetic analysis.

Authors:  C Schick; P A Pemberton; G P Shi; Y Kamachi; S Cataltepe; A J Bartuski; E R Gornstein; D Brömme; H A Chapman; G A Silverman
Journal:  Biochemistry       Date:  1998-04-14       Impact factor: 3.162

8.  Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells.

Authors:  Z Zou; A Anisowicz; M J Hendrix; A Thor; M Neveu; S Sheng; K Rafidi; E Seftor; R Sager
Journal:  Science       Date:  1994-01-28       Impact factor: 47.728

9.  Plasminogen-activator inhibitor type 2 (PAI-2) is a spontaneously polymerising SERPIN. Biochemical characterisation of the recombinant intracellular and extracellular forms.

Authors:  P Mikus; T Urano; P Liljeström; T Ny
Journal:  Eur J Biochem       Date:  1993-12-15

10.  A new variant of alpha-1-antitrypsin deficiency (Siiyama) associated with pulmonary emphysema.

Authors:  K Takabe; K Seyama; H Shinada; T Nouchi; Y Miyahara; T Nukiwa; K Miyake; K Tsukimoto; M Ichioka; F Marumo
Journal:  Intern Med       Date:  1992-05       Impact factor: 1.271

View more
  1 in total

1.  AFM Imaging Reveals Topographic Diversity of Wild Type and Z Variant Polymers of Human α1-Proteinase Inhibitor.

Authors:  Maria Gaczynska; Przemyslaw Karpowicz; Christine E Stuart; Malgorzata G Norton; Jeffrey H Teckman; Ewa Marszal; Pawel A Osmulski
Journal:  PLoS One       Date:  2016-03-23       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.